PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
26119076-0	2015	Anti-adipogenic effect of epiberberine is mediated by regulation of the Raf/MEK1/2/ERK1/2 and AMPKalpha/Akt pathways.	epiberberine	26-38	zinc fingers and homeoboxes 2	Homo sapiens	72-75
30391811-8	2019	As a result, epiberberine and fangchinoline with certain ACE inhibitory activities were screened out in the assay and validated.	epiberberine	13-25	angiotensin I converting enzyme	Homo sapiens	57-60
30155694-4	2018	Epiberberine and palmatine showed the strongest antagonistic activities against beta2-AR with IC50 values of 2.3 +- 0.2 muM and 2.6 +- 0.3 muM, respectively.	epiberberine	0-12	adrenoceptor beta 2	Homo sapiens	80-88
29343943-0	2018	The oral bioavailability, excretion and cytochrome P450 inhibition properties of epiberberine: an in vivo and in vitro evaluation.	epiberberine	81-93	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	40-55
26593426-4	2016	Furthermore, the antidyslipidemia effect of epiberberine on key genes involved in cholesterol biosynthesis, uptake, conversion and elimination such as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), low density lipoprotein receptor (LDL receptor), 7-alpha-hydroxylase (CYP7A1) and apical sodium dependent bile acid transporter (ASBT) were investigated.	epiberberine	44-56	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Mesocricetus auratus	151-191
26593426-4	2016	Furthermore, the antidyslipidemia effect of epiberberine on key genes involved in cholesterol biosynthesis, uptake, conversion and elimination such as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), low density lipoprotein receptor (LDL receptor), 7-alpha-hydroxylase (CYP7A1) and apical sodium dependent bile acid transporter (ASBT) were investigated.	epiberberine	44-56	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Mesocricetus auratus	193-198
26593426-4	2016	Furthermore, the antidyslipidemia effect of epiberberine on key genes involved in cholesterol biosynthesis, uptake, conversion and elimination such as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), low density lipoprotein receptor (LDL receptor), 7-alpha-hydroxylase (CYP7A1) and apical sodium dependent bile acid transporter (ASBT) were investigated.	epiberberine	44-56	low-density lipoprotein receptor	Mesocricetus auratus	201-233
26593426-6	2016	Epiberberine inhibited HMGCR mRNA and protein expressions and slightly reduced the protein level of ASBT, as well as dramatically up-regulated mRNA and protein expressions of CYP7A1 and LDL receptor.	epiberberine	0-12	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Mesocricetus auratus	23-28
26134304-7	2016	Additionally, coptisine, jatrorrhizine and epiberberine were substrates of all the hOCTs with the Km of 0.273-5.80 muM, whereas berberrubine was a substrate for hOCT1 and hOCT2, but not for hOCT3, the Km values were 1.27 and 1.66 muM, respectively.	epiberberine	43-55	solute carrier family 22 member 1	Homo sapiens	161-166
26134304-7	2016	Additionally, coptisine, jatrorrhizine and epiberberine were substrates of all the hOCTs with the Km of 0.273-5.80 muM, whereas berberrubine was a substrate for hOCT1 and hOCT2, but not for hOCT3, the Km values were 1.27 and 1.66 muM, respectively.	epiberberine	43-55	solute carrier family 22 member 2	Homo sapiens	171-176
26134304-7	2016	Additionally, coptisine, jatrorrhizine and epiberberine were substrates of all the hOCTs with the Km of 0.273-5.80 muM, whereas berberrubine was a substrate for hOCT1 and hOCT2, but not for hOCT3, the Km values were 1.27 and 1.66 muM, respectively.	epiberberine	43-55	solute carrier family 22 member 3	Homo sapiens	190-195
26134304-10	2016	The above data indicate that the tested alkaloids are potent inhibitors, and coptisine, jatrorrhizine, epiberberine and berberrubine are substrates of hOCT1, hOCT2 and/or hOCT3 with high affinity.	epiberberine	103-115	solute carrier family 22 member 1	Homo sapiens	151-156
26134304-10	2016	The above data indicate that the tested alkaloids are potent inhibitors, and coptisine, jatrorrhizine, epiberberine and berberrubine are substrates of hOCT1, hOCT2 and/or hOCT3 with high affinity.	epiberberine	103-115	solute carrier family 22 member 2	Homo sapiens	158-163
26134304-10	2016	The above data indicate that the tested alkaloids are potent inhibitors, and coptisine, jatrorrhizine, epiberberine and berberrubine are substrates of hOCT1, hOCT2 and/or hOCT3 with high affinity.	epiberberine	103-115	solute carrier family 22 member 3	Homo sapiens	171-176
26119076-3	2015	Here, we show that epiberberine had inhibitory effects on adipocyte differentiation and significantly decreased lipid accumulation by downregulating an adipocyte-specific transcription factor, sterol regulatory element-binding protein-1 (SREBP-1).	epiberberine	19-31	sterol regulatory element binding transcription factor 1	Homo sapiens	193-236
26119076-3	2015	Here, we show that epiberberine had inhibitory effects on adipocyte differentiation and significantly decreased lipid accumulation by downregulating an adipocyte-specific transcription factor, sterol regulatory element-binding protein-1 (SREBP-1).	epiberberine	19-31	sterol regulatory element binding transcription factor 1	Homo sapiens	238-245
26119076-4	2015	Furthermore, we observed that epiberberine markedly suppressed the differentiation-mediated phosphorylation of components of both the Raf/mitogen-activated protein kinase 1 (MEK1)/extracellular signal-regulated protein kinase 1/2 (ERK1/2) and AMP-activated protein kinase-alpha1 (AMPKalpha)/Akt pathways.	epiberberine	30-42	zinc fingers and homeoboxes 2	Homo sapiens	134-137
26119076-4	2015	Furthermore, we observed that epiberberine markedly suppressed the differentiation-mediated phosphorylation of components of both the Raf/mitogen-activated protein kinase 1 (MEK1)/extracellular signal-regulated protein kinase 1/2 (ERK1/2) and AMP-activated protein kinase-alpha1 (AMPKalpha)/Akt pathways.	epiberberine	30-42	mitogen-activated protein kinase 1	Homo sapiens	138-172
26119076-0	2015	Anti-adipogenic effect of epiberberine is mediated by regulation of the Raf/MEK1/2/ERK1/2 and AMPKalpha/Akt pathways.	epiberberine	26-38	mitogen-activated protein kinase kinase 1	Homo sapiens	76-82
26119076-0	2015	Anti-adipogenic effect of epiberberine is mediated by regulation of the Raf/MEK1/2/ERK1/2 and AMPKalpha/Akt pathways.	epiberberine	26-38	mitogen-activated protein kinase 3	Homo sapiens	83-89
26119076-4	2015	Furthermore, we observed that epiberberine markedly suppressed the differentiation-mediated phosphorylation of components of both the Raf/mitogen-activated protein kinase 1 (MEK1)/extracellular signal-regulated protein kinase 1/2 (ERK1/2) and AMP-activated protein kinase-alpha1 (AMPKalpha)/Akt pathways.	epiberberine	30-42	mitogen-activated protein kinase kinase 1	Homo sapiens	174-178
26119076-0	2015	Anti-adipogenic effect of epiberberine is mediated by regulation of the Raf/MEK1/2/ERK1/2 and AMPKalpha/Akt pathways.	epiberberine	26-38	AKT serine/threonine kinase 1	Homo sapiens	104-107
25612454-5	2014	The cocktail probe drugs method was imposed to determine the content change of metoprolol, dapsone, phenacetin, chlorzoxazone and tolbutamide simultaneously for evaluating the activity of CYP2D6, CYP3A4, CYP1A2, CYP2E1 and CYP2C9 under different concentrations of epiberberine in rat liver microsomes.	epiberberine	264-276	cytochrome P450, family 2, subfamily d, polypeptide 3	Rattus norvegicus	188-194
26119076-4	2015	Furthermore, we observed that epiberberine markedly suppressed the differentiation-mediated phosphorylation of components of both the Raf/mitogen-activated protein kinase 1 (MEK1)/extracellular signal-regulated protein kinase 1/2 (ERK1/2) and AMP-activated protein kinase-alpha1 (AMPKalpha)/Akt pathways.	epiberberine	30-42	mitogen-activated protein kinase 3	Homo sapiens	231-237
26119076-4	2015	Furthermore, we observed that epiberberine markedly suppressed the differentiation-mediated phosphorylation of components of both the Raf/mitogen-activated protein kinase 1 (MEK1)/extracellular signal-regulated protein kinase 1/2 (ERK1/2) and AMP-activated protein kinase-alpha1 (AMPKalpha)/Akt pathways.	epiberberine	30-42	AKT serine/threonine kinase 1	Homo sapiens	291-294
26119076-5	2015	In addition, gene expression of fatty acid synthase (FAS) was significantly inhibited by treatment with epiberberine during adipogenesis.	epiberberine	104-116	fatty acid synthase	Homo sapiens	32-51
26119076-5	2015	In addition, gene expression of fatty acid synthase (FAS) was significantly inhibited by treatment with epiberberine during adipogenesis.	epiberberine	104-116	fatty acid synthase	Homo sapiens	53-56
26119076-6	2015	These results indicate that the anti-adipogenic mechanism of epiberberine is associated with inhibition of phosphorylation of Raf/MEK1/ERK1/2 and AMPKalpha/Akt, followed by downregulation of the major transcription factors of adipogenesis, such as PPAR-gamma, C/EBP-alpha, and SREBP-1, and FAS.	epiberberine	61-73	zinc fingers and homeoboxes 2	Homo sapiens	126-129
26119076-6	2015	These results indicate that the anti-adipogenic mechanism of epiberberine is associated with inhibition of phosphorylation of Raf/MEK1/ERK1/2 and AMPKalpha/Akt, followed by downregulation of the major transcription factors of adipogenesis, such as PPAR-gamma, C/EBP-alpha, and SREBP-1, and FAS.	epiberberine	61-73	mitogen-activated protein kinase kinase 1	Homo sapiens	130-134
26119076-6	2015	These results indicate that the anti-adipogenic mechanism of epiberberine is associated with inhibition of phosphorylation of Raf/MEK1/ERK1/2 and AMPKalpha/Akt, followed by downregulation of the major transcription factors of adipogenesis, such as PPAR-gamma, C/EBP-alpha, and SREBP-1, and FAS.	epiberberine	61-73	mitogen-activated protein kinase 3	Homo sapiens	135-141
26119076-6	2015	These results indicate that the anti-adipogenic mechanism of epiberberine is associated with inhibition of phosphorylation of Raf/MEK1/ERK1/2 and AMPKalpha/Akt, followed by downregulation of the major transcription factors of adipogenesis, such as PPAR-gamma, C/EBP-alpha, and SREBP-1, and FAS.	epiberberine	61-73	AKT serine/threonine kinase 1	Homo sapiens	156-159
26119076-6	2015	These results indicate that the anti-adipogenic mechanism of epiberberine is associated with inhibition of phosphorylation of Raf/MEK1/ERK1/2 and AMPKalpha/Akt, followed by downregulation of the major transcription factors of adipogenesis, such as PPAR-gamma, C/EBP-alpha, and SREBP-1, and FAS.	epiberberine	61-73	peroxisome proliferator activated receptor gamma	Homo sapiens	248-258
26119076-6	2015	These results indicate that the anti-adipogenic mechanism of epiberberine is associated with inhibition of phosphorylation of Raf/MEK1/ERK1/2 and AMPKalpha/Akt, followed by downregulation of the major transcription factors of adipogenesis, such as PPAR-gamma, C/EBP-alpha, and SREBP-1, and FAS.	epiberberine	61-73	CCAAT enhancer binding protein alpha	Homo sapiens	260-271
26119076-6	2015	These results indicate that the anti-adipogenic mechanism of epiberberine is associated with inhibition of phosphorylation of Raf/MEK1/ERK1/2 and AMPKalpha/Akt, followed by downregulation of the major transcription factors of adipogenesis, such as PPAR-gamma, C/EBP-alpha, and SREBP-1, and FAS.	epiberberine	61-73	sterol regulatory element binding transcription factor 1	Homo sapiens	277-284
26119076-6	2015	These results indicate that the anti-adipogenic mechanism of epiberberine is associated with inhibition of phosphorylation of Raf/MEK1/ERK1/2 and AMPKalpha/Akt, followed by downregulation of the major transcription factors of adipogenesis, such as PPAR-gamma, C/EBP-alpha, and SREBP-1, and FAS.	epiberberine	61-73	fatty acid synthase	Homo sapiens	290-293
26119076-7	2015	Taken together, this study suggests that the anti-adipogenic effect of epiberberine is mediated by downregulation of the Raf/MEK1/ERK1/2 and AMPKalpha/Akt pathways during 3T3-L1 adipocyte differentiation.	epiberberine	71-83	zinc fingers and homeoboxes 2	Homo sapiens	121-124
26119076-7	2015	Taken together, this study suggests that the anti-adipogenic effect of epiberberine is mediated by downregulation of the Raf/MEK1/ERK1/2 and AMPKalpha/Akt pathways during 3T3-L1 adipocyte differentiation.	epiberberine	71-83	mitogen-activated protein kinase kinase 1	Homo sapiens	125-129
26119076-7	2015	Taken together, this study suggests that the anti-adipogenic effect of epiberberine is mediated by downregulation of the Raf/MEK1/ERK1/2 and AMPKalpha/Akt pathways during 3T3-L1 adipocyte differentiation.	epiberberine	71-83	mitogen-activated protein kinase 3	Homo sapiens	130-136
26119076-7	2015	Taken together, this study suggests that the anti-adipogenic effect of epiberberine is mediated by downregulation of the Raf/MEK1/ERK1/2 and AMPKalpha/Akt pathways during 3T3-L1 adipocyte differentiation.	epiberberine	71-83	AKT serine/threonine kinase 1	Homo sapiens	151-154
25660286-7	2015	Several compounds, such as berberine, berberrubine and epiberberine, dose-dependently inhibited PGE2 production in human KB cells, and the effects were similar in the presence or absence of TPA.	epiberberine	55-67	plasminogen activator, tissue type	Homo sapiens	190-193
25612454-0	2014	[Identification of metabolites of epiberberine in rat liver microsomes and its inhibiting effects on CYP2D6].	epiberberine	34-46	cytochrome P450, family 2, subfamily d, polypeptide 3	Rattus norvegicus	101-107
25612454-7	2014	Epiberberine showed significant inhibition on CYP2D6 with IC50 value of 35.22 mumol L(-1), but had no obvious inhibiting effect on the activities of CYP3A4, CYP1A2, CYP2E1 and CYP2C9.	epiberberine	0-12	cytochrome P450, family 2, subfamily d, polypeptide 3	Rattus norvegicus	46-52
25612454-8	2014	The results indicated that epiberberine may be caused drug interactions based on CYP2D6 enzyme.	epiberberine	27-39	cytochrome P450, family 2, subfamily d, polypeptide 3	Rattus norvegicus	81-87
21425377-9	2011	In conclusion, Huanglian showed in vitro inhibition of CYP2D6, the inhibition might be contributed mostly by protoberberine alkaloids, especially coptisine and epiberberine.	epiberberine	160-172	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	55-61
24164032-7	2013	Seven isoquinoline alkaloids, namely jatrorrhizine, epiberberine, columbamine, coptisine, corysamine, palmatine and berberine were identified to be active as the inhibitors of ACHE.	epiberberine	52-64	acetylcholinesterase (Cartwright blood group)	Homo sapiens	176-180
34664067-8	2021	UHPLC-fourier-transform mass spectrometry detection results revealed that five alkaloids showed obvious AChE inhibitory activities including coptisin, epiberberine, jatrorrhizine, berberine and palmatine.	epiberberine	151-163	acetylcholinesterase (Cartwright blood group)	Homo sapiens	104-108
15807993-4	2005	In addition, DNA fragmentation induced by SIN-1 was significantly decreased by the extract, and also by coptisine, epiberberine, jatrorhizine, groenlandicine and magnoflorine.	epiberberine	115-127	MAPK associated protein 1	Homo sapiens	42-47
15807993-5	2005	Moreover, treatment with berberine, coptisine, palmatine and epiberberine exerted a protective effect against G(0)/G(1)phase arrest of cell cycle induced by SIN-1.	epiberberine	61-73	MAPK associated protein 1	Homo sapiens	157-162
35504329-8	2022	By decreasing beta-catenin expression, increasing GSK-3beta expression and decreasing N-cadherin expression, increasing E-cadherin expression, which proved that epiberberine, berberrubine and dihydroberberine inhibited of metastasis of breast cancer cells through Wnt signaling pathway and reversed EMT except berberine.	epiberberine	161-173	catenin beta 1	Homo sapiens	14-26
35504329-8	2022	By decreasing beta-catenin expression, increasing GSK-3beta expression and decreasing N-cadherin expression, increasing E-cadherin expression, which proved that epiberberine, berberrubine and dihydroberberine inhibited of metastasis of breast cancer cells through Wnt signaling pathway and reversed EMT except berberine.	epiberberine	161-173	glycogen synthase kinase 3 alpha	Homo sapiens	50-59
35504329-8	2022	By decreasing beta-catenin expression, increasing GSK-3beta expression and decreasing N-cadherin expression, increasing E-cadherin expression, which proved that epiberberine, berberrubine and dihydroberberine inhibited of metastasis of breast cancer cells through Wnt signaling pathway and reversed EMT except berberine.	epiberberine	161-173	cadherin 2	Homo sapiens	86-96
35504329-8	2022	By decreasing beta-catenin expression, increasing GSK-3beta expression and decreasing N-cadherin expression, increasing E-cadherin expression, which proved that epiberberine, berberrubine and dihydroberberine inhibited of metastasis of breast cancer cells through Wnt signaling pathway and reversed EMT except berberine.	epiberberine	161-173	cadherin 1	Homo sapiens	120-130
33571918-0	2021	Epiberberine ameliorated diabetic nephropathy by inactivating the angiotensinogen (Agt) to repress TGFbeta/Smad2 pathway.	epiberberine	0-12	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	66-81
35597409-20	2022	Isoquinoline alkaloids, including berberine, jateorhizine, coptisine, epiberberine, columbamine, and palmatine, were substrates of hOCT1 and hOCT2, but not the indole alkaloids evodiamine and rutaecarpine.	epiberberine	70-82	solute carrier family 22 member 1	Homo sapiens	131-136
33963719-8	2021	Several key targets including AKT1, IL- 6, JUN, TNF and CASP3 were screened for molecular docking, which had good binding activities with berberrubine, epiberberine, stigmasterol and sitosterol.	epiberberine	152-164	AKT serine/threonine kinase 1	Homo sapiens	30-34
33963719-8	2021	Several key targets including AKT1, IL- 6, JUN, TNF and CASP3 were screened for molecular docking, which had good binding activities with berberrubine, epiberberine, stigmasterol and sitosterol.	epiberberine	152-164	interleukin 6	Homo sapiens	36-41
33963719-8	2021	Several key targets including AKT1, IL- 6, JUN, TNF and CASP3 were screened for molecular docking, which had good binding activities with berberrubine, epiberberine, stigmasterol and sitosterol.	epiberberine	152-164	tumor necrosis factor	Homo sapiens	48-51
33963719-8	2021	Several key targets including AKT1, IL- 6, JUN, TNF and CASP3 were screened for molecular docking, which had good binding activities with berberrubine, epiberberine, stigmasterol and sitosterol.	epiberberine	152-164	caspase 3	Homo sapiens	56-61
33748269-13	2021	The findings also suggest that several ingredients of ABR such as Baicalien, Copistine, Epiberberine, Kaempferol, and Palmatine have good affinity with IL6, suggesting the promising potential of ABR in treating bone trauma, likely through IL6.	epiberberine	88-100	interleukin 6	Homo sapiens	152-155
33748269-13	2021	The findings also suggest that several ingredients of ABR such as Baicalien, Copistine, Epiberberine, Kaempferol, and Palmatine have good affinity with IL6, suggesting the promising potential of ABR in treating bone trauma, likely through IL6.	epiberberine	88-100	interleukin 6	Homo sapiens	239-242
35597409-19	2022	RESULTS: Berberine, jateorhizine, coptisine, epiberberine, columbamine, demethyleneberberine, and berberrubine could significantly inhibit hOCT1 and hOCT2 activity.	epiberberine	45-57	solute carrier family 22 member 1	Homo sapiens	139-144
35597409-19	2022	RESULTS: Berberine, jateorhizine, coptisine, epiberberine, columbamine, demethyleneberberine, and berberrubine could significantly inhibit hOCT1 and hOCT2 activity.	epiberberine	45-57	POU class 2 homeobox 2	Homo sapiens	149-154
33571918-0	2021	Epiberberine ameliorated diabetic nephropathy by inactivating the angiotensinogen (Agt) to repress TGFbeta/Smad2 pathway.	epiberberine	0-12	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	83-86
33571918-0	2021	Epiberberine ameliorated diabetic nephropathy by inactivating the angiotensinogen (Agt) to repress TGFbeta/Smad2 pathway.	epiberberine	0-12	transforming growth factor alpha	Mus musculus	99-106
33571918-0	2021	Epiberberine ameliorated diabetic nephropathy by inactivating the angiotensinogen (Agt) to repress TGFbeta/Smad2 pathway.	epiberberine	0-12	SMAD family member 2	Mus musculus	107-112
33571918-13	2021	Noteworthy, Agt knockdown by siRNA significantly attenuated these beneficial efficacies exerted by EPI, indicating that Agt played a crucial role in the process of EPI improving DN.	epiberberine	99-102	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	12-15
33571918-13	2021	Noteworthy, Agt knockdown by siRNA significantly attenuated these beneficial efficacies exerted by EPI, indicating that Agt played a crucial role in the process of EPI improving DN.	epiberberine	99-102	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	120-123
33571918-13	2021	Noteworthy, Agt knockdown by siRNA significantly attenuated these beneficial efficacies exerted by EPI, indicating that Agt played a crucial role in the process of EPI improving DN.	epiberberine	164-167	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	12-15
33571918-13	2021	Noteworthy, Agt knockdown by siRNA significantly attenuated these beneficial efficacies exerted by EPI, indicating that Agt played a crucial role in the process of EPI improving DN.	epiberberine	164-167	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	120-123
33571918-14	2021	CONCLUSION: These findings suggested that EPI might be a potential drug for the treatment of DN dependent on the Agt-TGFbeta/Smad2 pathway.	epiberberine	42-45	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	113-116
33571918-14	2021	CONCLUSION: These findings suggested that EPI might be a potential drug for the treatment of DN dependent on the Agt-TGFbeta/Smad2 pathway.	epiberberine	42-45	transforming growth factor alpha	Mus musculus	117-124
33571918-14	2021	CONCLUSION: These findings suggested that EPI might be a potential drug for the treatment of DN dependent on the Agt-TGFbeta/Smad2 pathway.	epiberberine	42-45	SMAD family member 2	Mus musculus	125-130
32534357-10	2020	The apoptosis induced by EPI in MKN-45 cells would be effectively inhibited with the treatment of p53 siRNA and p53 inhibitor PFT-alpha.	epiberberine	25-28	tumor protein p53	Homo sapiens	98-101
32534357-10	2020	The apoptosis induced by EPI in MKN-45 cells would be effectively inhibited with the treatment of p53 siRNA and p53 inhibitor PFT-alpha.	epiberberine	25-28	tumor protein p53	Homo sapiens	112-115
32534357-12	2020	Animal experiments confirmed that EPI significantly alleviated tumor growth in MKN-45 xenograft mice via p53/Bax pathway.	epiberberine	34-37	transformation related protein 53, pseudogene	Mus musculus	105-108
32534357-12	2020	Animal experiments confirmed that EPI significantly alleviated tumor growth in MKN-45 xenograft mice via p53/Bax pathway.	epiberberine	34-37	BCL2-associated X protein	Mus musculus	109-112
32065882-3	2020	Among these protoberberine alkaloids, epiberberine potently inhibited LSD1 (IC50 = 0.14 +- 0.01 muM) and was highly selective to LSD1 over MAO-A/B.	epiberberine	38-50	lysine demethylase 1A	Homo sapiens	70-74
32065882-3	2020	Among these protoberberine alkaloids, epiberberine potently inhibited LSD1 (IC50 = 0.14 +- 0.01 muM) and was highly selective to LSD1 over MAO-A/B.	epiberberine	38-50	latexin	Homo sapiens	96-99
32065882-3	2020	Among these protoberberine alkaloids, epiberberine potently inhibited LSD1 (IC50 = 0.14 +- 0.01 muM) and was highly selective to LSD1 over MAO-A/B.	epiberberine	38-50	lysine demethylase 1A	Homo sapiens	129-133
32065882-3	2020	Among these protoberberine alkaloids, epiberberine potently inhibited LSD1 (IC50 = 0.14 +- 0.01 muM) and was highly selective to LSD1 over MAO-A/B.	epiberberine	38-50	monoamine oxidase A	Homo sapiens	139-146
32065882-4	2020	Furthermore, epiberberine could induce the expression of CD86, CD11b and CD14 in THP-1 and HL-60 cells, confirming its cellular activity of inducing acute myeloid leukemia (AML) cells differentiation.	epiberberine	13-25	CD86 molecule	Homo sapiens	57-61
32065882-4	2020	Furthermore, epiberberine could induce the expression of CD86, CD11b and CD14 in THP-1 and HL-60 cells, confirming its cellular activity of inducing acute myeloid leukemia (AML) cells differentiation.	epiberberine	13-25	integrin subunit alpha M	Homo sapiens	63-68
32065882-4	2020	Furthermore, epiberberine could induce the expression of CD86, CD11b and CD14 in THP-1 and HL-60 cells, confirming its cellular activity of inducing acute myeloid leukemia (AML) cells differentiation.	epiberberine	13-25	CD14 molecule	Homo sapiens	73-77
32065882-4	2020	Furthermore, epiberberine could induce the expression of CD86, CD11b and CD14 in THP-1 and HL-60 cells, confirming its cellular activity of inducing acute myeloid leukemia (AML) cells differentiation.	epiberberine	13-25	GLI family zinc finger 2	Homo sapiens	81-86
32065882-5	2020	Moreover, epiberberine prolonged the survival of THP-1 cells bearing mice and inhibited the growth of AML cells in vivo without obvious global toxicity.	epiberberine	10-22	GLI family zinc finger 2	Homo sapiens	49-54